Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05181462 | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.(TRIFOUR) | completed | Phase 1 / Phase 2 | 117 | Cantargia ABINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT05955833 | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study(HER Image) | completed | N/A | 6 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 |
| clinicaltrials |
| NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Integro TheranosticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT03612648 | Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma | completed | N/A | 77 | Washington University School of MedicineOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04245176 | Genetic Testing for All Breast Cancer Patients (GET FACTS) | completed | N/A | 400 | Brigham and Women's HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment(TORCHLIGHT) | completed | Phase 3 | 531 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02705859 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)(Panther) | completed | Phase 1 | 26 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05263362 | An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)(STARLINGS) | completed | — | 775 | Erasmus Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07521397 | Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.(ΗE_10R/22) | completed | — | 5,358 | Hellenic Cooperative Oncology GroupOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02595905 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | completed | Phase 2 | 344 | National Cancer Institute (NCI)NIH | 2 | Apr 8, 2026 | clinicaltrials |
| NCT04081779 | Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study | completed | N/A | 261 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02129686 | A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients | completed | N/A | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04721886 | Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer | completed | Early Phase 1 | 25 | Thomas Jefferson UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04877821 | The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC(NeoSACT) | completed | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06133465 | Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management | completed | — | 1,063 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03947151 | Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer(DEGASTIM) | completed | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07126522 | Virtual Support Platform (HERCaRE Application) for the Improvement of Survivorship Among Black Breast Cancer Survivors | completed | N/A | 45 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03586297 | Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer | completed | — | 49 | Hackensack Meridian HealthOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06133647 | Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System | completed | — | 8 | Methodist Health SystemOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07455110 | EORTC Quality of Life Measurement in Males With Breast Cancer(BR Male) | completed | — | 65 | Helios University Hospital WuppertalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04539938 | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer(HER2CLIMB-04) | completed | Phase 2 | 70 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03709446 | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | completed | Phase 1 / Phase 2 | 17 | Joseph SparanoOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05340413 | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.(RADIOLA) | completed | Phase 2 | 65 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06036875 | CARE: Cancer Risk Perception and Women of Color | completed | — | 324 | Mayo ClinicOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05012813 | Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer | completed | N/A | 28 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05528263 | Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)(PACT) | completed | N/A | 89 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07416409 | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | completed | — | 80 | Deraya UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02530489 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03301350 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | completed | Phase 2 | 29 | University of Wisconsin, MadisonOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02212860 | Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy(SIGNAL 2) | completed | N/A | 139 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | completed | Phase 1 | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06335108 | Postoperative Pain After Breast Surgery Under Tumescent Local Anaesthesia Versus General Anaesthesia ( TLA-001 ) | completed | — | 349 | University Hospital TuebingenOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT02158507 | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | completed | N/A | 20 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06388304 | THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence(THRIVE) | completed | N/A | 39 | Joanna ArchOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06996548 | Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)(Neuro-Sarc) | completed | — | 120 | Gazi UniversityOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT04852926 | Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.(ENVIE) | completed | — | 25 | University Hospital, LilleOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT00757302 | Intraoperative Gamma Camera for Breast Cancer Surgery | completed | Phase 3 | 110 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 27, 2026source: clinicaltrials